Gastrointestinal-type chemotherapy prolongs survival in an atypical primary ovarian mucinous carcinoma: A case report

Table 1 Laboratory data

Variable	On presentation	Reference range
Blood routine examination
White blood cell count	6.69 × 109/L	3.5-9.5 × 109/L
Neutrophils	5.33 × 109/L	1.8-6.3 × 109/L
Lymphocytes	1.02 × 109/L	1.1-3.2 × 109/L
Monocytes	0.31 × 109/L	0.1-0.6 × 109/L
Eosinophils	0.01 × 109/L	0.02-0.52 × 109/L
Basophils	0.02 × 109/L	0-0.06 × 109/L
Hemoglobin	124 g/L	115-150 g/L
Platelet	161 × 109/L	125-350 × 109/L
Sodium	147 mmol/L	137-147 mmol/L
Potassium	2.9 mmol/L	3.5-5.3 mmol/L
Chloride	105 mmol/L	99-110 mmol/L
Calcium	2.62 mmol/L	2.11-2.52 mmol/L
Albumin	44.9 g/L	20-55 g/L
Aspartate aminotransferase	23 U/L	13-35 U/L
Alanine aminotransferase	17 U/L	7-40 U/L
Bilirubin	18.91 μmol/L	3-22 μmol/L
Creatinine	81 μmol/L	31-132 μmol/L
Urea nitrogen	3.12 mmol/L	2.6-7.5 mmol/L
Cystatin c	0.88 mg/L	0.10-0.45 mg/L

Table 2 Tumor markers

Variable	Reference range	First visit	Second hospitalisation	Third hospitalisation	Forth hospitalisation	Last dose of chemotherapy
CEA (ng/mL)	0-3.4	44.04	28.69	17.18	5.67	3.21
CA242 (IU/mL)	0-15	18.08	14.45	10.81	7.85	8.52
CA19-9 (U/mL)	0-39	100.8	60.81	33.83	18.39	16.70
AFP (ng/mL)	0-7.02	9.03	8.09	7.16	6.15	6.75
CA15-3 (U/mL)	0-25	30.37	22.58	20.13	15.84	14.70
CA125 (U/mL)	0-35	137.4	40.68	21.11	11.66	12.10
HE4 (pmol/L)	< 140	105.7	72.3	70.1	64.4	50.7

CEA: Carcinoembryonic antigen; CA: Carbohydrate antigen; HE4: Human epididymis protein 4.

Table 3 Mutation profiling by next-generation sequencing

Gene	Variation	Mutation	Cervical lymph node	Cervical neoplasm	Peripheral Blood
Tumor-specific mutation
CCNE1	Gene amplification		-	3.1-fold	-
DLL3	Gene amplification		-	3.2-fold	-
KRAS	Gene amplification		5.2-fold	9.8-fold	-
PTK2	Gene amplification		-	2.2-fold	-
RB1	Splice site mutation	c.1421+29_1498+69del	8.5%	52.0%	0.4%
STK11	Single copy deletion		-	Single copy deletion	-
VHL	Single copy deletion		-	Single copy deletion	-
DDR2	Truncation mutation	c.1646C>G(p.S549*)	10.4%	20.8%	0.8%
EPHA3	Missense mutation	c.2515G>A(p.E839K)	-	1.1%	-
ETV6	Missense mutation	c.369G>C(p.Q123H)	14.0%	23.5%	0.9%
GNAS	Missense mutation	c.1984G>A(p.E662K)	13.4%	-	0.6%
TAP1	Missense mutation	c.149C>T(p.P50L)	2.0%	-	-
TP53	Splice site mutation	c.376-1G>A	18.2%	69.9%	0.8%
TP53	Single copy deletion	-	-	Single copy deletion	-
Germline mutation		Mutation
BRCA2	Truncation mutation	c.8629G>T(p.E2877*)
EPCAM	Frameshift mutation	c.843delT(p.G282Efs*21)